To print: Select File and then Print from your browser's menu

Title: Oxymorphone Long-Term Trial Data Presented at the American Academy Of Physical Medicine And Rehabilitation Meeting

"Oxymorphone Long-Term Trial Data Presented at the American Academy Of Physical Medicine And Rehabilitation Meeting"

Long-Term Open-Label Data Presented for Patients with Chronic, Moderate to Severe Low Back Pain and Chronic Moderate to Severe Osteoarthritis Pain HONOLULU, HAWAII -- November 13, 2006 -- Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc., presented data from several clinical trials of Opana® ER (oxymorphone HCl) extended-release tablets CII. Results from these open-label studies were presented last week at the 67th Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R). Opana® ER was approved in June 2006 by the U.S. Food and Drug Administration (FDA) for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. Two of the studies presented at the meeting were open-label, one-year extensions of placebo-controlled, blinded studies in patients with moderate-to-severe chronic low back pain and osteoarthritis pain. Study results demonstrated that Opana® ER provided durable, effective pain relief in those patients who completed the full one year study period. "Pain can be a chronic condition, and long-term trials involving pain treatments are extremely important," said David A.H. Lee, MD, PhD, Chief Scientific Officer of Endo Pharmaceuticals. "These trial results demonstrate that, in these patients with chronic pain resulting from lower back conditions or osteoarthritis, Opana® ER provided safe, durable pain relief." Additionally, data from a third open-label study showed that long-term treatment with Opana® ER in opioid-naïve patients with moderate-to-severe chronic pain who completed the trial resulted in significant improvements in all pain quality of life measures, which were maintained throughout the course of the study period. Dr. Lee continued, "Pain can often interfere with normal everyday activities and as a result can have a dramatic impact on patients' quality of life. This trial indicates that Opana® ER minimized this disruption due to pain in these patients' daily lives." Long-Term Effectiveness, Dosing and Tolerability of Opana® ER in Patients with Chronic Lower Back Pain This open-label extension study evaluated the effectiveness, dosing and tolerability of Opana® ER in 93 patients who had completed a previous short-term, randomized, double-blind, placebo-controlled trial of Opana ER for moderate-to-severe chronic lower back pain. Patients were given Opana® ER twice a day for one year with the dose adjusted as needed and were allowed Opana® (immediate-release oxymorphone) as rescue medication for breakthrough pain as needed. Opana® ER provided durable effective pain relief throughout the one-year trial 90.2% of patients rated their pain medication as good, very good, or excellent at final visit Pain was measured by the Brief Pain Inventory (BPI) 0-10 point scale (higher scores indicate worst pain). Throughout the one-year study, the average pain scores ranged from 4.4-4.9 and at final visit, it was 4.6 (±2.1). Mean daily doses of Opana® ER and Opana® increased from 93.7 mg to 135.2 mg and from 13.9 mg to 21.3 mg respectively over the one year period. Commonly reported adverse events (<10%) included influenza, back pain, headache, upper respiratory tract infection, insomnia and urinary tract infection. Long-Term Safety and Effectiveness of Opana® ER in Patients with Chronic Osteoarthritis Pain This open-label extension study evaluated the safety, effectiveness and dosing of Opana® ER in 61 patients who had completed a previous randomized, placebo-controlled trial of Opana® ER for moderate to severe chronic pain associated with osteoarthritis of the knee or hip. Patients taking active drug in the previous trial were given Opana® ER twice a day at their prior dose for one year, whereas patients previously receiving placebo were given Opana® ER 20 mg twice a day for one year. Opana® ER provided consistent and effective pain relief throughout the one-year trial At each study visit 85% or more of patients rated their pain medication as "excellent," "very good," or "good". Pain was measured by Pain Recall Scores (Visual Analog Scale [VAS]). Recall scores for least, worst, and average pain decreased over the first six weeks and stabilized thereafter. There was only a modest increase in the mean daily dose over the one-year period; week 1 (49.3 mg) to week 10 (55.2 mg) and week 52 (62.0 mg). Most discontinuations were due to nonserious adverse events, which were more commonly reported in previously opioid-naïve patients. The most commonly reported adverse events (>10%) included constipation, nausea, somnolence, diarrhea, headache and arthralgia. Effective Dose Titration and Long-Term Treatment with Opana® ER Improves Quality of Life in Opioid-Naïve Patients with Chronic Moderate-to-Severe Pain This open-label study evaluated Opana® ER on pain reduction and improvements in quality of life in 60 patients during long-term treatment for moderate to severe chronic pain. In this study, 126 opioid-naïve adults with moderate or severe chronic pain who responded poorly to nonopioid analgesics were gradually titrated to a stable dose of Opana® ER for three of five consecutive days. Stabilized patients continued Opana® ER treatment for up to five additional months. Sixty patients completed the follow-up period. Immediate-release Opana® was available as a rescue medication for breakthrough pain. Patients rated the impact of pain on their daily activities with a variety of quality of life measures using a 0-10 scale (0 represented no interference, 10 represented complete interference). Opana® ER provided significant improvements in all patient-reported pain quality of life measures (including activity, work, enjoyment of life, walking, sleep, mood, and relationships) Treatment with Opana® ER improved pain quality of life measures by 60%–70% and effects were maintained throughout the trial (P <.001 for all measures at all months). The mean daily dose remained stable (range: 27.8–30.8 mg) with 68.1% of patients using immediate-release Opana® as a rescue medication for breakthrough pain at some point during the course of the maintenance period. Mean daily dose of rescue medication ranged from 1.3-1.5 tablets per day. Most common adverse events were constipation, nausea, and nasopharyngitis. Important Safety Information Opana® ER and Opana® are opioid agonists and Schedule II controlled substances with an abuse liability similar to morphine. Opana® ER and Opana® can be abused in a manner similar to other opioid agonists, legal or illicit. WARNING: Opana® ER contains oxymorphone, which is a morphine-like opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. Oxymorphone can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing OPANA ER in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. Opana® ER is an extended-release oral formulation of oxymorphone indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Opana® ER is NOT intended for use as a prn analgesic. Opana® ER Tablets are to be swallowed whole and are not to be broken, chewed, dissolved, or crushed. Taking broken, chewed, dissolved, or crushed OPANA ER TABLETS leads to rapid release and absorption of a potentially fatal dose of oxymorphone. Patients must not consume alcoholic beverages, or prescription or non-prescription medications containing alcohol, while on OPANA ER therapy. The co-ingestion of alcohol with OPANA ER may result in increased plasma levels and a potentially fatal overdose of oxymorphone. Opana® ER is not indicated for pain in the immediate post-operative period (12-24 hours following surgery), or if pain is mild or not expected to persist for an extended period of time. Opana® ER and Opana® are contraindicated in patients with a known hypersensitivity to oxymorphone hydrochloride, morphine analogs such as codeine, or any of the other ingredients of Opana® ER and Opana®; in patients with moderate or severe hepatic impairment or in any situation where opioids are contraindicated. Respiratory depression is the chief hazard of Opana® ER and Opana®, particularly in elderly or debilitated patients. The most common adverse drug reactions (≥10%) in all clinical trials for Opana« ER were nausea, constipation, dizziness (excluding vertigo), vomiting, pruritus, somnolence, headache, increased sweating, and sedation. The most common adverse drug reactions (≥10%) reported in all clinical trials for Opana« were nausea and pyrexia. About Pain Pain of all types is under-treated in our society; however, experts concur optimal management of chronic pain requires around-the-clock coverage with an analgesic agent. More than 50 million Americans suffer from chronic pain and 25 million suffer from acute pain. Pain costs the United States more than $100 billion annually. Additionally, pain contributes to more than 50 million lost workdays each year. About Opana ER and Opana® Tablets Opana® ER and Opana® tablets were formulated using oxymorphone hydrochloride, a semisynthetic, pure mu-opioid agonist that had been available previously only as an injectable formulation. Both products have been proven to achieve effective relief in multiple moderate-to-severe pain models, in opioid-naïve and opioid-experienced patients. Both Opana® ER and Opana® are available by prescription only. Opana® ER's clinical profile has demonstrated that it can be dosed consistently on a twice-daily basis and is well-tolerated when titrated effectively. Opana® ER has also shown maintenance of effective pain control at a stable dose over the three-month period of the pivotal clinical trials, which the company believes highlights the durability of its analgesic effect. Opana® ER utilizes a patented delivery system that was specifically developed to provide continuous delivery of medication over a 12-hour period, helping patients maintain a steady level of pain relief. Experts agree that patients suffering from moderate-to-severe chronic pain which is present much or all of the day need around-the-clock coverage with an analgesic agent to sustain pain relief. Opana® ER has been studied in a wide range of chronic pain conditions, including low back pain, osteoarthritis pain, and cancer pain. Endo developed Opana® ER using Penwest Pharmaceuticals' proprietary time-release technology, TIMERx®-N. Immediate release Opana® is indicated for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate. Opana® has been studied in multiple post-operative pain models, including orthopedic and abdominal procedures. Immediate-release Opana® is a proprietary product developed by Endo. SOURCE: Endo Pharmaceuticals Holdings Inc.

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.